CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease

Cardiovasc Diabetol. 2022 Sep 15;21(1):185. doi: 10.1186/s12933-022-01626-1.

Abstract

Chemokines are key components in the pathology of chronic diseases. Chemokine CC motif ligand 7 (CCL7) is believed to be associated with cardiovascular disease, diabetes mellitus, and kidney disease. CCL7 may play a role in inflammatory events by attracting macrophages and monocytes to further amplify inflammatory processes and contribute to disease progression. However, CCL7-specific pathological signaling pathways need to be further confirmed in these chronic diseases. Given the multiple redundancy system among chemokines and their receptors, further experimental and clinical studies are needed to clarify whether direct CCL7 inhibition mechanisms could be a promising therapeutic approach to attenuating the development of cardiovascular disease, diabetes mellitus, and kidney disease.

Keywords: Cardiovascular disease; Chemokine; Chemokine CC motif ligand 7; Chronic kidney disease; Diabetes mellitus; Diabetic kidney disease.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Diseases*
  • Chemokine CCL7 / metabolism
  • Chemokines / metabolism
  • Diabetes Mellitus*
  • Humans
  • Kidney Diseases*
  • Ligands

Substances

  • CCL7 protein, human
  • Chemokine CCL7
  • Chemokines
  • Ligands